PROTAC Amorphous Solid Dispersion for Stable Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
PROTAC molecules face challenges with poor water solubility, low oral absorption, and significant bioavailability issues, particularly affected by food intake, limiting their effectiveness in vivo applications.
Innovation Solution
A pharmaceutical composition comprising an amorphous solid dispersion (ASD) of PROTAC compounds with a surfactant, hydrophilic polymer, and optional acid, enhancing bioavailability by at least 2-fold compared to non-ASD forms, and reducing variability between fed and fasted states.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PROTAC compounds are used to target proteins, then protein degradation efficacy is improved, but water solubility deteriorates
Solution Approach 1:
The patent introduces food as an intermediary substance that facilitates the dissolution and absorption of PROTAC compounds. The food matrix acts as a mediator between the lipophilic PROTAC and the aqueous gastrointestinal environment, enabling improved solubility and bioavailability without compromising the protein degradation efficacy.
Solution Approach 2:
The patent changes the physical-chemical parameters of PROTAC compounds by modifying their molecular structure (e.g., adjusting log P values, molecular weight, and exposing polar surface area) to optimize the balance between membrane permeability and solubility, thereby improving water solubility while maintaining degradation efficacy.
2Ease of operation
If PROTAC compounds are administered orally, then convenience is improved, but oral absorption deteriorates
Solution Approach 1:
Food serves as a critical intermediary that enhances oral absorption of PROTAC compounds. The patent demonstrates that co-administration with food significantly improves bioavailability by facilitating dissolution and absorption processes in the gastrointestinal tract, thereby enabling reliable oral absorption while maintaining administration convenience.
Solution Approach 2:
The patent modifies key pharmacokinetic parameters including bioavailability, Cmax, and AUC by optimizing PROTAC compound properties and formulation conditions, achieving consistent and reliable oral absorption across different dietary states.
3Quantity of substance
If PROTAC compounds are administered with food, then solubility is improved, but absorption variability increases
Solution Approach 1:
The patent optimizes multiple physical-chemical parameters of PROTAC compounds including log P, molecular weight, and polar surface area to achieve consistent absorption behavior. By carefully controlling these parameters, the patent reduces food-effect variability while maintaining improved solubility.
Solution Approach 2:
The patent employs feedback mechanisms through clinical pharmacokinetic studies to characterize and understand food effects on PROTAC absorption. This feedback information is used to optimize dosing strategies and formulation designs to minimize absorption variability while maintaining solubility benefits.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ASD formulation significantly improves PROTAC bioavailability, achieving consistent absorption regardless of food intake and providing enhanced therapeutic efficacy.
Implementation Method 1
a pharmaceutical composition comprising an amorphous solid dispersion comprising a PROTAC compound
Implementation Method 2
The ASD comprises a PROTAC compound, a surfactant, and a hydrophilic polymer
Implementation Method 3
a hydrophilic polymer in an amount of about 10 mg to about 500 mg
Data Source
AI summary
Proteolysis Targeting Chimeras (PROTACs) are heterobifunctional degraders that specifically eliminate targeted proteins by hijacking the ubiquitin-proteasome system (UPS). Provided are pharmaceutical compositions which include a mixture of a PROTAC, a hydrophilic polymer, a surfactant, and optionally an acid and an adsorbent. Also described are methods for preparing and using such pharmaceutical compositions. In one aspect, disclosed herein is an amorphous solid dispersion comprising PROTAC.